See all $CTSO articles @ Daily Dose
CytoSorbents Corporation (OTCBB: CTSO) is a critical-care focused therapeutic device company using blood purification to treat life-threatening illnesses. These are common, major conditions seen in the intensive care unit (ICU), such as sepsis and infection, severe trauma, burns, lung injury, and pancreatitis, that afflicts millions of people each year yet lacks effective therapies, leading to a mortality rate that often exceeds 30%. Failure of multiple organs, such as the lungs, heart, kidneys and liver, is the leading causes of death from these conditions, for which very little can be done today. Hospital acquired infections are another leading cause of death in the ICU. CytoSorbents is developing novel and advanced blood purification therapies designed to actively prevent, mitigate, or reverse the development of organ failure and infection, thereby potentially reducing illness severity and helping patients to heal and recover faster. Ultimately the goal is to improve patient outcome and save healthcare costs. Nearly 1% of the US gross domestic product (GDP), or approximately $90 billion, is spent on critical care annually in the US, and billions of dollars are lost by hospitals each year due to a lack of effective therapies.
Dr. Phillip Chan, Cytosorbents ($CTSO) with Stock News Now
Keywords:
- CytoSorb
- HemoDefend
- Cytokine Storm and Cytokines
- Sepsis, septic shock, severe sepsis
- Systemic inflammatory response syndrome, SIRS,
- Acute respiratory distress syndrome, ARDS
- Acute lung injury, ALI
- Transfusion associated lung injury, TRALI
- Transfusion medicine
- Cardiopulmonary bypass
- Inflammation and influenza